Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed recurrent or unresponsive, metastatic renal cell, non-small cell lung, or breast cancer that has been treated previously with standard surgery, radiotherapy, chemotherapy, or immunotherapy or for which no available treatment options currently exist
• Confirmed overexpression of interleukin-4 receptors
• Measurable disease (lesions greater than 10 mm by CT scan) OR
• Evaluable disease
• No prior or concurrent clinically significant brain metastases
• Hormone receptor status:
• * Not specified
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Sex:
• Male or female
• Menopausal status:
• Not specified
• Performance status:
• Karnofsky 70-100%
• Life expectancy:
• More than 12 weeks
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• Transaminases no greater than 1.5 times ULN
• Albumin at least 2.5 g/dL
• Hepatitis B surface antigen negative
• Hepatitis C antibody negative
• No prior or concurrent hepatic disease (e.g., hepatitis or alcoholic liver disease)
• Renal:
• Creatinine no greater than 2.0 mg/dL
• Cardiovascular:
• See Surgery
• Electrocardiogram normal
• MUGA scan normal
• No congestive heart failure
• No cardiac arrhythmia requiring treatment
• No myocardial infarction
• No clinical evidence of coronary artery disease (unless there is a cardiac evaluation and evidence of adequate coronary function by a stress test or angiography)
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception for 4 weeks before, during, and for at least 3 months after study
• No concurrent underlying medical condition that would preclude study or cannot be controlled
• No active infection
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• See Disease Characteristics
• Chemotherapy:
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• Endocrine therapy:
• Not specified
• Radiotherapy:
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy
• Surgery:
• See Disease Characteristics
• At least 1 year since prior surgery or angioplasty for coronary artery disease
• Other:
• At least 28 days since prior experimental drugs and recovered